{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:42:16Z","timestamp":1792201336155,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11102-026-01766-7","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:15:07Z","timestamp":1792199707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Should radiotherapy be repositioned in the contemporary management of acromegaly?"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6117-0081","authenticated-orcid":false,"given":"Luigi","family":"di Filippo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Terenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"1766_CR1","doi-asserted-by":"crossref","unstructured":"Castinetti F, Piazzola C, Ayuk J et al (2026) Pituitary Society Delphi Consensus on the Role of Radiotherapy for Pituitary Adenomas. Pituitary. [In press]","DOI":"10.1007\/s11102-026-01759-6"},{"issue":"11","key":"1766_CR2","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","volume":"21","author":"S Melmed","year":"2025","unstructured":"Melmed S, di Filippo L, Fleseriu M et al (2025) Consensus on acromegaly therapeutic outcomes: an update. Nat Rev Endocrinol 21(11):718\u2013737. https:\/\/doi.org\/10.1038\/s41574-025-01148-2","journal-title":"Nat Rev Endocrinol"},{"issue":"19","key":"1766_CR3","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMra2409076","volume":"393","author":"A Giustina","year":"2025","unstructured":"Giustina A, Colao A, Acromegaly (2025) N Engl J Med 393(19):1926\u20131939. https:\/\/doi.org\/10.1056\/NEJMra2409076","journal-title":"N Engl J Med"},{"issue":"1","key":"1766_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.17925\/EE.2024.20.1.9","volume":"20","author":"MM Uygur","year":"2024","unstructured":"Uygur MM, Villanova M, Frara S, Giustina A (2024) Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly. touchREV Endocrinol 20(1):37\u201342. https:\/\/doi.org\/10.17925\/EE.2024.20.1.9","journal-title":"touchREV Endocrinol"},{"issue":"2","key":"1766_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12020-023-03317-7","volume":"80","author":"A Giustina","year":"2023","unstructured":"Giustina A, di Filippo L, Uygur MM, Frara S (2023) Modern approach to resistant acromegaly. Endocrine 80(2):303\u2013307. https:\/\/doi.org\/10.1007\/s12020-023-03317-7","journal-title":"Endocrine"},{"issue":"1","key":"1766_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF et al (2024) Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7\u201322. https:\/\/doi.org\/10.1007\/s11102-023-01360-1","journal-title":"Pituitary"},{"issue":"3","key":"1766_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11060-020-03552-2","volume":"148","author":"R Singh","year":"2020","unstructured":"Singh R, Didwania P, Lehrer EJ et al (2020) Stereotactic radiosurgery for acromegaly: an international systematic review and meta-analysis of clinical outcomes. J Neurooncol 148(3):401\u2013418. https:\/\/doi.org\/10.1007\/s11060-020-03552-2","journal-title":"J Neurooncol"},{"issue":"3","key":"1766_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/neuros\/nyy178","volume":"84","author":"D Ding","year":"2019","unstructured":"Ding D, Mehta GU, Patibandla MR et al (2019) Stereotactic Radiosurgery for Acromegaly: An International Multicenter Retrospective Cohort Study. Neurosurgery 84(3):717\u2013725. https:\/\/doi.org\/10.1093\/neuros\/nyy178","journal-title":"Neurosurgery"},{"issue":"1","key":"1766_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/BF03349183","volume":"29","author":"M Gola","year":"2006","unstructured":"Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A (2006) Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 29(1):86\u201393. https:\/\/doi.org\/10.1007\/BF03349183","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"1766_CR10","doi-asserted-by":"publisher","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","volume":"105","author":"SL Samson","year":"2020","unstructured":"Samson SL, Nachtigall LB, Fleseriu M et al (2020) Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. J Clin Endocrinol Metab 105(10):e3785\u2013e3797. https:\/\/doi.org\/10.1210\/clinem\/dgaa526","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1766_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1210\/clinem\/dgae385","volume":"110","author":"MR Gadelha","year":"2024","unstructured":"Gadelha MR, Casagrande A, Strasburger CJ et al (2024) Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine. J Clin Endocrinol Metab 110(1):228\u2013237. https:\/\/doi.org\/10.1210\/clinem\/dgae385","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1766_CR12","doi-asserted-by":"publisher","first-page":"e1050","DOI":"10.1210\/clinem\/dgaf579","volume":"111","author":"BMK Biller","year":"2026","unstructured":"Biller BMK, Casagrande A, Elenkova A et al (2026) Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment. J Clin Endocrinol Metab 111(4):e1050\u2013e1063. https:\/\/doi.org\/10.1210\/clinem\/dgaf579","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1766_CR13","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1210\/clinem\/dgae707","volume":"110","author":"D Ferone","year":"2025","unstructured":"Ferone D, Freda P, Katznelson L et al (2025) Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1. J Clin Endocrinol Metab 110(6):1729\u20131739. https:\/\/doi.org\/10.1210\/clinem\/dgae707","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1766_CR14","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1210\/endrev\/bnaf020","volume":"46","author":"MR Gadelha","year":"2025","unstructured":"Gadelha MR, Wildemberg LE, Marques NV, Kasuki L (2025) Medical Treatment of Acromegaly: Navigating the Present, Shaping the Future. Endocr Rev 46(6):838\u2013855. https:\/\/doi.org\/10.1210\/endrev\/bnaf020","journal-title":"Endocr Rev"},{"issue":"2","key":"1766_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/ejendo\/lvag148","volume":"195","author":"S Allas","year":"2026","unstructured":"Allas S, Ravel G, Farrell C et al (2026) A randomized first-in-human study of a novel growth hormone receptor peptide antagonist ALXN2420 in healthy subjects. Eur J Endocrinol 195(2):320\u2013328. https:\/\/doi.org\/10.1093\/ejendo\/lvag148","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"1766_CR16","doi-asserted-by":"publisher","first-page":"bqag090","DOI":"10.1210\/endocr\/bqag090","volume":"167","author":"K Kurylo","year":"2026","unstructured":"Kurylo K, Bouchard PR, Milton MN et al (2026) Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly. Endocrinology 167(9):bqag090. https:\/\/doi.org\/10.1210\/endocr\/bqag090","journal-title":"Endocrinology"},{"issue":"12 Suppl 1","key":"1766_CR17","doi-asserted-by":"publisher","first-page":"S146","DOI":"10.1210\/clinem\/dgag144","volume":"111","author":"K Schilbach","year":"2026","unstructured":"Schilbach K, Strasburger CJ (2026) What is the future of acromegaly therapy? J Clin Endocrinol Metab 111(12 Suppl 1):S146\u2013S155. https:\/\/doi.org\/10.1210\/clinem\/dgag144","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1766_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40618-017-0614-1","volume":"40","author":"A Giustina","year":"2017","unstructured":"Giustina A, Arnaldi G, Bogazzi F et al (2017) Pegvisomant in acromegaly: an update. J Endocrinol Invest 40(6):577\u2013589. https:\/\/doi.org\/10.1007\/s40618-017-0614-1","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"1766_CR19","doi-asserted-by":"publisher","first-page":"101898","DOI":"10.1016\/j.beem.2024.101898","volume":"38","author":"L Albano","year":"2024","unstructured":"Albano L, Losa M, Garbin E, Pompeo E, Barzaghi LR, Mortini P (2024) Efficacy and safety of radiosurgery in acromegaly. Best Pract Res Clin Endocrinol Metab 38(4):101898. https:\/\/doi.org\/10.1016\/j.beem.2024.101898","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"8","key":"1766_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S2213-8587(22)00160-7","volume":"10","author":"R Hamblin","year":"2022","unstructured":"Hamblin R, Vardon A, Akpalu J et al (2022) Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance. Lancet Diabetes Endocrinol 10(8):581\u2013588. https:\/\/doi.org\/10.1016\/S2213-8587(22)00160-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1766_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11102-026-01639-z","volume":"29","author":"A Giustina","year":"2026","unstructured":"Giustina A, di Filippo L, Fleseriu M et al (2026) Consensus on acromegaly complications: an update. Pituitary 29(3):76 Published 2026 Apr 29. https:\/\/doi.org\/10.1007\/s11102-026-01639-z","journal-title":"Pituitary"},{"issue":"Supplement1","key":"1766_CR22","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1210\/clinem\/dgag114","volume":"111","author":"A Giustina","year":"2026","unstructured":"Giustina A, Fleseriu M (2026) Acromegaly complications: an update. J Clin Endocrinol Metab 111(Supplement1):S51\u2013S63. https:\/\/doi.org\/10.1210\/clinem\/dgag114","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"1766_CR23","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/s0002-9149(99)80721-8","volume":"75","author":"A Giustina","year":"1995","unstructured":"Giustina A, Boni E, Romanelli G, Grassi V, Giustina G (1995) Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 75(15):1042\u20131047. https:\/\/doi.org\/10.1016\/s0002-9149(99)80721-8","journal-title":"Am J Cardiol"},{"key":"1766_CR24","doi-asserted-by":"publisher","unstructured":"di Filippo L, Acanfora M, Bolamperti S, Terenzi U, Bonomo M, Giustina A (2026) Osteometabolic complications in patients with secreting pituitary adenomas: Is there an impact of gender? Pituitary. ;29(3):96. Published 2026 May 29. https:\/\/doi.org\/10.1007\/s11102-026-01667-9","DOI":"10.1007\/s11102-026-01667-9"},{"issue":"6","key":"1766_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s11102-025-01573-6","volume":"28","author":"S Chiloiro","year":"2025","unstructured":"Chiloiro S, Palumbo C, Giampietro A et al (2025) Acromegaly treatment and bone: a bidirectional relationship. Pituitary 28(6):124 Published 2025 Nov 8. https:\/\/doi.org\/10.1007\/s11102-025-01573-6","journal-title":"Pituitary"},{"issue":"3","key":"1766_CR26","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1210\/jcem.85.3.6464","volume":"85","author":"AM Landolt","year":"2000","unstructured":"Landolt AM, Haller D, Lomax N et al (2000) Octreotide may act as a radioprotective agent in acromegaly. J Clin Endocrinol Metab 85(3):1287\u20131289. https:\/\/doi.org\/10.1210\/jcem.85.3.6464","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1766_CR27","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1210\/jc.2005-0311","volume":"90","author":"F Castinetti","year":"2005","unstructured":"Castinetti F, Taieb D, Kuhn JM et al (2005) Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 90(8):4483\u20134488. https:\/\/doi.org\/10.1210\/jc.2005-0311","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1766_CR28","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3171\/jns.2007.106.5.833","volume":"106","author":"BE Pollock","year":"2007","unstructured":"Pollock BE, Jacob JT, Brown PD, Nippoldt TB (2007) Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg 106(5):833\u2013838. https:\/\/doi.org\/10.3171\/jns.2007.106.5.833","journal-title":"J Neurosurg"},{"issue":"1","key":"1766_CR29","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1210\/jc.2006-1412","volume":"92","author":"C Parkinson","year":"2007","unstructured":"Parkinson C, Burman P, Messig M, Trainer PJ (2007) Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 92(1):190\u2013195. https:\/\/doi.org\/10.1210\/jc.2006-1412","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1766_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1530\/EJE-08-0705","volume":"160","author":"M Marazuela","year":"2009","unstructured":"Marazuela M, Lucas T, Alvarez-Escol\u00e1 C et al (2009) Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol 160(4):535\u2013542. https:\/\/doi.org\/10.1530\/EJE-08-0705","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1766_CR31","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11102-023-01345-0","volume":"26","author":"A Giustina","year":"2023","unstructured":"Giustina A, Uygur MM, Frara S et al (2023) Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers. Pituitary 26(5):583\u2013596. https:\/\/doi.org\/10.1007\/s11102-023-01345-0","journal-title":"Pituitary"},{"issue":"4","key":"1766_CR32","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11102-024-01397-w","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Uygur MM, Frara S et al (2024) Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE). Pituitary 27(4):381\u2013388. https:\/\/doi.org\/10.1007\/s11102-024-01397-w","journal-title":"Pituitary"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01766-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01766-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01766-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:15:08Z","timestamp":1792199708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01766-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1766"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01766-7","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"25 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not required","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.D.F. research activities are partly supported by the Glucocorticoid Induced Osteoporosis Skeletal Endocrinology Group (GIOSEG). All other authors declare no conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"165"}}